Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.69
OMER's Cash to Debt is ranked higher than
54% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 108.89 vs. OMER: 0.69 )
OMER' s 10-Year Cash to Debt Range
Min: 0.69   Max: 23.84
Current: 0.69

0.69
23.84
Equity to Asset -1.11
OMER's Equity to Asset is ranked lower than
54% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OMER: -1.11 )
OMER' s 10-Year Equity to Asset Range
Min: -4.21   Max: 0.7
Current: -1.11

-4.21
0.7
F-Score: 1
Z-Score: -23.08
M-Score: -10.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -3157.25
OMER's Operating margin (%) is ranked higher than
51% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -66.46 vs. OMER: -3157.25 )
OMER' s 10-Year Operating margin (%) Range
Min: -3157.25   Max: -605.88
Current: -3157.25

-3157.25
-605.88
Net-margin (%) -2487.25
OMER's Net-margin (%) is ranked higher than
52% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -53.69 vs. OMER: -2487.25 )
OMER' s 10-Year Net-margin (%) Range
Min: -2487.25   Max: -630.99
Current: -2487.25

-2487.25
-630.99
ROA (%) -240.68
OMER's ROA (%) is ranked lower than
52% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -18.63 vs. OMER: -240.68 )
OMER' s 10-Year ROA (%) Range
Min: -240.68   Max: -33.98
Current: -240.68

-240.68
-33.98
ROC (Joel Greenblatt) (%) -5379.77
OMER's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 840 Companies
in the Global Biotechnology industry.

( Industry Median: -179.37 vs. OMER: -5379.77 )
OMER' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5379.77   Max: -1856.1
Current: -5379.77

-5379.77
-1856.1
Revenue Growth (%) -15.70
OMER's Revenue Growth (%) is ranked higher than
65% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. OMER: -15.70 )
OMER' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 7.7
Current: -15.7

0
7.7
EBITDA Growth (%) 0.80
OMER's EBITDA Growth (%) is ranked higher than
82% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: -9.80 vs. OMER: 0.80 )
OMER' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 0.8
Current: 0.8

0
0.8
EPS Growth (%) 0.50
OMER's EPS Growth (%) is ranked higher than
82% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. OMER: 0.50 )
OMER' s 10-Year EPS Growth (%) Range
Min: 0   Max: 0.5
Current: 0.5

0
0.5
» OMER's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

OMER Guru Trades in Q1 2013

Jim Simons 91,037 sh (New)
» More
Q2 2013

OMER Guru Trades in Q2 2013

Jim Simons 82,281 sh (-9.62%)
» More
Q3 2013

OMER Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2013

OMER Guru Trades in Q4 2013

Paul Tudor Jones 10,807 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with OMER



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 202.90
OMER's P/S is ranked lower than
86% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. OMER: 202.90 )
OMER' s 10-Year P/S Range
Min: 15.16   Max: 237.17
Current: 202.9

15.16
237.17
EV-to-EBIT 5.00
OMER's EV-to-EBIT is ranked higher than
87% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. OMER: 5.00 )
OMER' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 5.70
OMER's Price/Median PS Value is ranked lower than
51% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. OMER: 5.70 )
OMER' s 10-Year Price/Median PS Value Range
Min: 0.59   Max: 5.82
Current: 5.7

0.59
5.82
Forward Rate of Return (Yacktman) -46.97
OMER's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: -8.97 vs. OMER: -46.97 )
OMER' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -156.4   Max: -21.2
Current: -46.97

-156.4
-21.2

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:3O8.Germany
Omeros Corporation is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system. It derives product candidates from its proprietary PharmacoSurgery platform that is designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The Company's product candidates comprise OMS302, which is in Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program evaluating the product candidates safety and ability to improve postoperative joint function and reduce pain following arthroscopic partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. It also engages in developing proprietary compositions that comprise peroxisome proliferator-activated receptor gamma agonists for the treatment and prevention of addiction to substances of abuse. The Company's pipeline of preclinical product development programs includes PDE10 for schizophrenia/cognitive disorders; PDE7 for addictions and compulsive disorders, and movement disorders; MASP2 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; and Plasmin for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors programs for multiple disorders.
» More Articles for OMER

Headlines

Articles On GuruFocus.com
comment on OMER Mar 06 2013 
Follow Up on a Speculative Options Bet May 27 2011 
Another Two Speculative Options Bets May 13 2011 

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide